Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Report Conclusions Valid Despite Underlying Data Problems, IG Says

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Office of Inspector General withdraws its report on 340B drug pricing because of incorrect data mistakenly supplied by CMS. OIG plans to conduct a wider review of the 340B program before reissuing the report.

You may also be interested in...



Hospitals Eligible For Discounted Drugs Would Increase Under Legislation

A bill being drafted by the Senate Republican leadership would facilitate hospital participation in the federal Sec. 340B drug discount program through model contracts and relaxation of inventory management requirements, Public Hospital Pharmacy Coalition General Counsel von Oehsen says.

Hospitals Eligible For Discounted Drugs Would Increase Under Legislation

A bill being drafted by the Senate Republican leadership would facilitate hospital participation in the federal Sec. 340B drug discount program through model contracts and relaxation of inventory management requirements, Public Hospital Pharmacy Coalition General Counsel von Oehsen says.

340B Drug Pricing Data Should Be Listed On Secure Website, IG Recommends

The HHS Inspector General estimates that 340B entities paid an additional $41.1 mil. on outpatient drugs in September 2002 because they could not verify the ceiling price. HRSA has begun updating contact information and 340B participation status in real-time.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel